|
|
|
|
| LEADER |
02943nam a22003255i 4500 |
| 001 |
978-1-4471-3103-8 |
| 005 |
20191024111841.0 |
| 007 |
cr nn 008mamaa |
| 008 |
121227s1980 xxk| s |||| 0|eng d |
| 020 |
|
|
|a 9781447131038
|
| 024 |
7 |
|
|a 10.1007/978-1-4471-3103-8
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 100 |
1 |
|
|a Folb, P. I.
|e author.
|
| 245 |
1 |
4 |
|a The Safety of Medicines
|b Evaluation and Prediction /
|c by P. I. Folb.
|
| 250 |
|
|
|a 1st ed. 1980.
|
| 260 |
# |
# |
|a London :
|b Springer London :
|b Imprint: Springer,
|c 1980.
|
| 300 |
|
|
|a XII, 106 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a 1. Animal testing and early studies in humans -- 1.1. Introduction -- 1.2. Animal investigations -- 1.3. Factors influencing animal data -- 1.4. Extrapolation of data from animals to man -- 1.5. Metabolite-mediated toxicity -- 1.6. Early administration of medicines to man -- 1.7. Summary and conclusions -- 2. Prediction of teratogenic potential of a new medicine -- 2.1. Drug utilisation during pregnancy -- 2.2. The thalidomide model of drug-induced fetal damage -- 2.3. The spectrum of teratogenic effects -- 2.4. Prediction of the teratogenic potential of a new medicine -- 2.5. Decision-taking in practice -- 2.6. Summary and conclusions -- 3. Prediction of dependence-producing potential of a new drug -- 3.1. The features of drug dependence in man -- 3.2. Clinical profiles of drug dependence -- 3.3 Profile of a drug likely to produce dependence -- 3.4. Strategy in evaluation of dependence-potential -- 3.5. Summary and conclusions -- 4. Prediction of carcinogenic potential of a new medicine -- 4.1. The risks of drug-induced neoplasia in man -- 4.2. Profile of the high-risk medicine -- 4.3. Animal studies -- 4.4. Interpretation of animal data -- 4.5. In vitro tests -- 4.6. Summary and conclusions -- 5. The prediction of adverse drug interactions -- 5.1. The incidence and spectrum of drug-drug interactions -- 5.2. Clinically important adverse drug interactions -- 5.3. Prediction of adverse drug interactions -- 5.4. Clinical guidelines -- 5.5. Fixed-ratio combinations -- 5.6. Potential interactions of single-entity medicines -- 5.7. Summary and conclusions -- 6. Monitoring drug safety in clinical practice -- 6.1. Introduction -- 6.2. The diagnosis of adverse drug reactions in practice -- 6.3. Physicians’ evaluations of adverse drug reactions -- 6.4. Reporting and monitoring of adverse drug reactions -- 6.5. Risk-benefit evaluations -- 6.6. Summary and conclusions.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Internal medicine.
|
| 650 |
|
0 |
|a Pharmacy.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Internal Medicine.
|
| 650 |
2 |
4 |
|a Pharmacy.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-1-4471-3103-8
|